文献速递胸部肿瘤

Poziotinib 治疗既往治疗后携带 HER2 外显子 20 插入突变的非小细胞肺癌:ZENITH20-2 试验

Poziotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial.
PubMed 文献 · J Clin Oncol · 2021-11-29

ZENITH20 是一项多中心、多队列、开放标签 II 期研究,评估 poziotinib(16 mg 每日一次)在既往治疗的晚期或转移性 HER2 外显子 20 插入突变非小细胞肺癌患者中的疗效与安全性。2017 年 10 月至 2021 年 3 月共治疗 90 例患者,中位既往治疗线数为 2,客观缓解率为 27.8%(95% CI 18.9 至 38.2),疾病控制率为 70.0%(95% CI 59.4 至 79.2),中位无进展生存期为 5.5 个月(95% CI 3.9 至 5.8)。

要点

  • 客观缓解率 27.8%(95% CI 18.9 至 38.2),90 例中 25 例达部分缓解。
  • 疾病控制率 70.0%(95% CI 59.4 至 79.2),74% 患者肿瘤缩小,中位缩小 22%。
  • 3 级及以上治疗相关不良事件包括皮疹(48.9%)、腹泻(25.6%)、口腔炎(24.4%);76.7% 患者减量。

核心结论

  • Poziotinib 在既往治疗的 HER2 外显子 20 插入突变非小细胞肺癌患者中显示出抗肿瘤活性。

研究设计与样本

  • ZENITH20 为多中心、多队列、开放标签 II 期研究,评估 poziotinib 在晚期或转移性非小细胞肺癌患者中的疗效。
  • 队列 2 中患者接受 poziotinib 16 mg 每日一次。
  • 主要终点为独立评审委员会(RECIST v1.1)评估的客观缓解率;次要终点包括疾病控制率、缓解持续时间、无进展生存期、安全性和耐受性,并评估生活质量。
  • 2017 年 10 月至 2021 年 3 月共治疗 90 例患者,中位既往治疗线数为 2(范围 1-6)。

主要发现

  • 中位随访 9.0 个月,客观缓解率为 27.8%(95% CI 18.9 至 38.2),90 例中 25 例达部分缓解。
  • 疾病控制率为 70.0%(95% CI 59.4 至 79.2);74% 患者肿瘤缩小,中位缩小 22%。
  • 中位无进展生存期为 5.5 个月(95% CI 3.9 至 5.8);中位缓解持续时间为 5.1 个月(95% CI 4.2 至 5.5)。
  • 无论既往治疗线数和类型、是否存在中枢神经系统转移以及 HER2 突变类型,均观察到临床获益。
  • 3 级及以上治疗相关不良事件包括皮疹(48.9%)、腹泻(25.6%)和口腔炎(24.4%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Insertion mutations in Erb-b2 receptor tyrosine kinase 2 gene (ERBB2 or HER2) exon 20 occur in 2%-5% of non-small-cell lung cancers (NSCLCs) and function as an oncogenic driver. Poziotinib, a tyrosine kinase inhibitor, was evaluated in previously treated patients with NSCLC with HER2 exon 20 insertions. METHODS: ZENITH20, a multicenter, multicohort, open-label phase II study, evaluated poziotinib in patients with advanced or metastatic NSCLC. In cohort 2, patients received poziotinib (16 mg) once daily. The primary end point was objective response rate evaluated by independent review committee (RECIST v1.1); secondary outcome measures were disease control rate, duration of response, progression-free survival, and safety and tolerability. Quality of life was assessed. RESULTS: Between October 2017 and March 2021, 90 patients with a median of two prior lines of therapy (range, 1-6) were treated. With a median follow-up of 9.0 months, objective response rate was 27.8% (95% CI, 18.9 to 38.2); 25 of 90 patients achieved a partial response. Disease control rate was 70.0% (95% CI, 59.4 to 79.2). Most patients (74%) had tumor reduction (median reduction 22%). Median progression-free survival was 5.5 months (95% CI, 3.9 to 5.8); median duration of response was 5.1 months (95% CI, 4.2 to 5.5). Clinical benefit was seen regardless of lines and types of prior therapy, presence of central nervous system metastasis, and types of HER2 mutations. Grade 3 or higher treatment-related adverse events included rash (48.9%), diarrhea (25.6%), and stomatitis (24.4%). Most patients had poziotinib dose reductions (76.7%), with median relative dose intensity of 71.5%. Permanent treatment discontinuation because of treatment-related adverse events occurred in 13.3% of patients. CONCLUSION: Poziotinib demonstrates antitumor activity in previously treated patients with HER2 exon 20 insertion NSCLC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Le X, Cornelissen R, Garassino M, et al. Poziotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial. J Clin Oncol. 2021. PMID: 34843401. doi:10.1200/JCO.21.01323

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。